Translational genomics in cancer research: converting profiles into personalized cancer medicine

Cancer Biology and Medicine

Volumn 10, Issue 4, 2013, Pages 214-220

  Patel, Lalit ^a,b   Parker, Brittany ^a,b   Yang, Da ^a   Zhang, Wei ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Genomics; Personalized medicine; Translation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER GENOMICS; CANCER RESEARCH; FUSION GENE; GENOMICS; HUMAN; ONCOGENE; OVARY CANCER; PERSONALIZED MEDICINE; REVIEW;

EID: 84891324023     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2013.04.005     Document Type: Review

References (60)

1. Davies J J, Wilson I M, Lam W L. Array CGH technologies and their applications to Cancer genomes. Chromosome Res 2005;13:237-248.
2. Dutt A, Beroukhim R. Single nucleotide polymorphism array analysis of Cancer. Curr Opin Oncol 2007;19:43-49.
3. Schulze A, Downward J. Navigating gene expression using microarrays-a technology review. Nat Cell Biol 2001;3:E190-195.
4. Metzker M L. Sequencing technologies-the next generation. Nat Rev Genet 2010;11:31-46.
5. Collins F S, Barker A D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007;296:50-57.
6. International Cancer Genome Consortium, Hudson T J, Anderson W, Artez A, Barker A D, Bell C, et al. International network of cancer genome projects. Nature 2010;464:993-998.
7. Stephens P J, Tarpey P S, Davies H, Van Loo P, Greenman C, Wedge D C, et al. The landscape of Cancer genes and mutational processes in breast cancer. Nature 2012;486:400-404.
8. Barbieri C E, Baca S C, Lawrence M S, Demichelis F, Blattner M, Theurillat J P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and Med12 mutations in prostate cancer. Nat Genet 2012;44:685-689.
9. Wei X, Walia V, Lin J C, Teer J K, Prickett T D, Gartner J, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011;43:442-446.
10. Ellis M J, Ding L, Shen D, Luo J, Suman V J, Wallis J W, et al. Wholegenome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-360.
11. Berger M F, Lawrence M S, Demichelis F, Drier Y, Cibulskis K, Sivachenko A Y, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-220.
12. Weinstein J N, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003;326:909-920.
13. Weinstein J N. Searching for pharmacogenomic markers: the synergy between omic and hypothesis-driven research. Dis Markers 2001;17:77-88.
14. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A A, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
15. Garnett M J, Edelman E J, Heidorn S J, Greenman C D, Dastur A, Lau K W et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-575.
16. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
17. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot C V, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 2013;23:186-199.
18. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012;22:398-406.
19. Carro M S, Lim W K, Alvarez M J, Bollo R J, Zhao X, Snyder E Y, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-325.
20. Whittemore A S, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
21. Risch H A, McLaughlin J R, Cole D E, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
22. Rubin S C, Blackwood M A, Bandera C, Behbakht K, Benjamin I, Rebbeck T R, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998;178:670-677.
23. Pal T, Permuth-Wey J, Betts J A, Krischer J P, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816.
24. Press J Z, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
25. King M C, Marks J H, Mandell J B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
26. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-1333.
27. Levine D A, Argenta P A, Yee C J, Marshall D S, Olvera N, Bogomolniy F, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227.
28. Vencken P M, Kriege M, Hoogwerf D, Beugelink S, van der Burg M E, Hooning M J, et al. Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346-1352.
29. Cass I, Baldwin R L, Varkey T, Moslehi R, Narod S A, Karlan B Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-2195.
30. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-25.
31. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 2007;6:113-119.
32. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A K, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-1565.
33. Bolton K L, Chenevix-Trench G, Goh C, Sadetzki S, Ramus S J, Karlan B Y, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382-390.
34. Hyman D M, Zhou Q, Iasonos A, Grisham R N, Arnold A G,Phillips M F, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian Cancer. Cancer 2012;118:3703-3709.
35. Farmer H, McCabe N, Lord C J, Tutt A N, Johnson D A, Richardson T B, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
36. Bryant H E, Schultz N, Thomas H D, Parker K M, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917.
37. Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer 2011;30:463-471.
38. Fong P C, Boss D S, Yap T A, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
39. Audeh M W, Carmichael J, Penson R T, Friedlander M, Powell B, Bell-McGuinn K M, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
40. Fong P C, Yap T A, Boss D S, Carden C P, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-2519.
41. Gelmon K A, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-861.
42. Dreazen O, Klisak I, Jones G, Ho W G, Sparkes R S, Gale R P. Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1987;67:319-324.
43. Schuster S C. Next-generation sequencing transforms today's biology. Nat Methods 2008;5:16-18.
44. Tomlins S A, Rhodes D R, Perner S, Dhanasekaran S M, Mehra R, Sun X W, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
45. Parker B C, Annala M J, Cogdell D E, Granberg K J, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013;123:855-865.
46. Warrell R P Jr, Frankel S R, Miller W H Jr, Scheinberg D A, Itri L M, Hittelman W N, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-1393.
47. Wu Y M, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-647.
48. Singh D, Chan J M, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-1235.
49. Williams S V, Hurst C D, Knowles M A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
50. Pendergast A M, Muller A J, Havlik M H, Maru Y, Witte O N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a nonphosphotyrosine-dependent manner. Cell 1991;66:161-171.
51. Pendergast A M, Quilliam L A, Cripe L D, Bassing C H, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993;75:175-185.
52. Persson M, Andren Y, Mark J, Horlings H M, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 2009;106: 18740-18744.
53. Esgueva R, Perner S, J LaFargue C, Scheble V, Stephan C, Lein M, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010;23:539-546.
54. Shah N P, Tran C, Lee F Y, Chen P, Norris D, Sawyers C L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
55. Nahta R, Yu D, Hung M C, Hortobagyi G N, Esteva F J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-280.
56. Engelman J A, Jaenne P A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
57. Villanueva J, Vultur A, Lee J T, Somasundaram R, Fukunaga-Kalabis M, Cipolla A K, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-695.
58. Michor F, Iwasa Y, Nowak M A. Dynamics of cancer progression. Nat Rev Cancer 2004;4:197-205.
59. Govindan R, Ding L, Griffith M, Subramanian J, Dees N D, Kanchi K L, Maher C A, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
60. Ding L, Ley T J, Larson D E, Miller C A, Koboldt D C, Welch J S, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-510.